Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review | Zendy

Meng Zhao | Zendy; Haiying Zhou | Zendy; Jun Xu | Zendy; Feng Zhang | Zendy; Wenbin Wei | Zendy; Ningpu Liu | Zendy

Open Access

Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review

Author(s) -

Meng Zhao,

Haiying Zhou,

Jun Xu,

Feng Zhang,

Wenbin Wei,

Ningpu Liu

Publication year - 2017

Publication title -

international journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 29

eISSN - 2227-4898

pISSN - 2222-3959

DOI - 10.18240/ijo.2017.03.14

Subject(s) - medicine , ranibizumab , ophthalmology , visual acuity , photodynamic therapy , fluorescein angiography , bevacizumab , indocyanine green angiography , fundus (uterus) , hazard ratio , retrospective cohort study , macular degeneration , surgery , confidence interval , chemotherapy , chemistry , organic chemistry

To report a cohort of patients with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT) followed by intravitreal ranibizumab injection 24-48h later, and to compare the results between eyes with PCV treated by PDT followed by intravitreal anti-vascular endothelial growth factor (VEGF) injection and intravitreal anti-VEGF injection followed by PDT by Meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research